Kidney Week

Abstract: FR-PO0836

Dyslipidemia Patterns in Proteinuric Glomerular Diseases

Session Information

• Glomerular Diseases: Practice and New Concepts Shaping Modern Care
  October 23, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Mulukutla, Swetha, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, United States

Swetha Mulukutla

• Shen, Carol L., Cohen Children's Medical Center, New York, New York, United States

Carol L. Shen, MD

• Castellanos, Laura J., Cohen Children's Medical Center, New York, New York, United States

Laura J. Castellanos, MD

• Basalely, Abby Miriam, Cohen Children's Medical Center, New York, New York, United States

Abby Miriam Basalely, MD, MS

• Frank, Rachel, Cohen Children's Medical Center, New York, New York, United States

Rachel Frank, CNN, RN

• Sethna, Christine B., Cohen Children's Medical Center, New York, New York, United States

Christine B. Sethna, MD, MEd

Group or Team Name

• CureGN

Background

Dyslipidemia is a well-recognized feature of proteinuric glomerular disease, yet longitudinal data characterizing lipid abnormalities, statin utilization, and their relationship to kidney outcomes remain limited.

Methods

This study used CureGN, a longitudinal cohort study of adults/children with proteinuric glomerular diseases (MCD, FSGS, MN, IgA). Dyslipidemia was defined according to age-specific lipid ranges. GEE examined the association of dyslipidemia with glomerular filtration rate (eGFR) over time. Cox regression with time-varying covariates evaluated associations with 40% eGFR decline, end stage kidney disease (ESKD), and complete remission adjusted for diagnosis, age, sex, baseline eGFR, and urine protein/creatinine.

Results

Among 1,498 adults (46 yrs, 43.3% female) and 533 children (11 yrs, 41.8% female), dyslipidemia was prevalent at baseline (adult 67.7% vs. pediatric 57.7%, p<0.001). Abnormal triglycerides were more common in children (50.6% vs. 41.4%, p<0.001), while abnormal total cholesterol was more prevalent in adults (46.1% vs. 40.8%, p=0.02). Statin use was lower in pediatrics across visits (10.8–22.6% vs. 54.0–61.5%, p<0.001), with the highest rates in MN and lowest in MCD (Figure). Dyslipidemia was associated with higher eGFR over time (ß=1.32, 95% CI 0.21–2.43, p=0.019), but not 40% eGFR decline (HR 1.47, 95% CI 0.97–2.23, p=0.07), ESKD (HR 0.92, 95% CI 0.58–1.47, p=0.72), or complete remission (HR 0.78, 95% CI 0.52–1.18, p=0.24) in adjusted models. Age-stratified results were similar.

Conclusion

Despite the high prevalence of dyslipidemia in glomerular diseases, statin use remains low, especially in children. Dyslipidemia was associated with higher eGFR over time (likely reflecting preserved kidney function in nephrotic presentations), but not with other kidney outcomes. Prospective studies of lipid-lowering therapy in glomerular disease are needed.

Funding

• NIDDK Support